INDIVIOR (INDV) Company Report

Indivior has implemented an "Indivior Action Agenda" to maximize business value, including a $150 million reduction in OPEX and a commitment that 2026 OPEX will not exceed $450 million. This is expected to lead to significant margin improvement in 2026.
The company is optimizing its international business by reducing its presence from 41 countries to 4 countries (Canada, Australia, France, Germany), which represent 77% of forecasted net revenue and 94% of forecasted EBITDA for the Rest of World business.
Commercial support for OPVEE has been ceased due to unfavorable market dynamics, allowing for greater focus on maximizing the core asset, SUBLOCADE.
A significant untapped opportunity exists for SUBLOCADE in commercially covered patients, who represent 60% of covered lives but only 25% of prescriptions. Indivior plans aggressive investment in consumer (DTC) efforts to drive long-acting injectable market penetration, currently at 8%.
Indivior's R&D pipeline includes Indivior 6001 and Indivior 2000 with phase two data readouts expected in early Q2 2026. Future M&A will target commercial stage assets with $200 million+ peak sales potential in adjacent therapeutic areas.

2 days ago

Transcript

Indivior Outlines Strategic Vision, Cost Optimization, and SUBLOCADE Growth Initiatives

INDV

Guidance Update

New Projects/Investments

M&A

Indivior has implemented an "Action Agenda" to maximize business value, which includes removing $150 million of OPEX and targeting 2026 OPEX not exceeding $450 million.
The company is optimizing its Rest of World business, reducing its presence from 41 countries to 4 (Canada, Australia, France, and Germany), which collectively represent 77% of forecasted net revenue and 94% of forecasted EBITDA.
Commercial support for OPVEE has been discontinued due to market dynamics and lack of synergy with the SUBLOCADE business.
Indivior is prioritizing investment in SUBLOCADE, which has 88% payer access and a market share stabilized in the mid-70%, with plans for aggressive consumer campaigns to drive long-acting injectable penetration.
Future growth will also involve commercial stage acquisitions with over $200 million peak sales potential in adjacent therapeutic areas.

2 days ago

Transcript

Indivior Concludes Legacy U.S. Department of Justice Matter

INDV

Legal Proceedings

Indivior PLC announced on November 20, 2025, the conclusion of its legacy U.S. Department of Justice (DOJ) matter.
The company resolved the matter by paying the outstanding obligation of $295 million.
This payment was funded with Indivior's cash on hand, leading to the termination of the resolution agreement with the DOJ.
CEO Joe Ciaffoni stated that this action removes a significant liability and simplifies the company's capital structure.

Nov 20, 2025, 9:01 PM

Press Release

Indivior PLC to Redomicile to U.S. with New Nasdaq-Listed Holding Company

INDV

Delisting/Listing Issues

M&A

Proxy Vote Outcomes

Indivior PLC is undergoing a redomiciliation from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc., a new Delaware corporation, as its ultimate holding company.
Under the scheme, Indivior Shareholders will receive one Indivior Pharmaceuticals Share for every one Indivior Share held.
The new Indivior Pharmaceuticals Shares will be listed on Nasdaq, with trading anticipated to commence at the end of January 2026, following the expected effective date of the Scheme.
The strategic move aims to maximize the benefits of the Group's U.S. stock listing, including expanding U.S. capital markets presence, increasing U.S. equity indexation, and simplifying corporate governance.
Post-redomiciliation, Indivior Pharmaceuticals will comply with U.S. corporate governance standards, and the U.K. City Code on Takeovers and Mergers will no longer apply.

Nov 14, 2025, 2:05 PM

8-K

Indivior discusses Q3 results, Sublocade growth, and cost savings

INDV

Guidance Update

Layoffs

New Projects/Investments

Indivior reported a strong Q3 beat and raise, with Sublocade showing 10% growth this year, and announced $150 million in cost savings for next year, reducing OPEX to no more than $450 million.
The company expects Sublocade sales to surpass $1 billion, with current year guidance of $825 million-$845 million, and aims to increase long-acting injectable (LAI) penetration from 8% to 20-30%.
The $150 million cost savings include a 30% reduction in headcount and the discontinuation of non-essential spend and certain product/market activities.
Indivior plans to acquire new commercial stage assets with potential revenue of at least $200 million and has a history of $400 million in share buybacks.

Nov 13, 2025, 1:40 PM

Transcript

Indivior Discusses Strong Q3 Results, SUBLOCADE Growth, and Cost Savings at Stifel Conference

INDV

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Indivior reported strong Q3 results, marking its second consecutive beat and raise, with the stock reaching a seven-year high.
The company upgraded its 2025 guidance for SUBLOCADE to $825 million-$845 million and anticipates the product will eventually surpass $1 billion in sales.
Indivior announced $150 million in cost savings for next year, targeting OpEx of no more than $450 million, primarily through a headcount reduction of over 30% and discontinuing non-essential spend.
The company is executing its "Indivior Action Agenda," focusing on generating momentum in 2025 and accelerating growth in 2026, with an expected pickup in SUBLOCADE's growth rate and immediate bottom-line acceleration.
Indivior is exploring M&A opportunities for commercial-stage assets with potential revenues of at least $200 million in new therapeutic areas, and has a history of returning capital to shareholders through buybacks.

Nov 13, 2025, 1:40 PM

Transcript

Indivior Reports Strong Q3 Results, Announces $150 Million Cost Savings, and Sublocade Growth Expectations

INDV

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Indivior reported a strong Q3 beat and raise, marking its second consecutive quarterly beat and raise, with the stock reaching a seven-year high.
The company announced $150 million in cost savings for next year, reducing OPEX to no more than $450 million and expecting EBITDA margins to increase from the mid-30s to the mid-40s.
Sublocade is guided for 10% growth this year, with revenue growth and accelerated bottom-line growth expected in 2026, and is anticipated to eventually surpass $1 billion in sales.
Indivior plans to pursue commercial stage assets for future growth, targeting products with at least $200 million in potential revenue.

Nov 13, 2025, 1:40 PM

Transcript

Indivior Presents New Real-World Evidence on SUBLOCADE at AMCP Nexus 2025

INDV

Indivior presented new real-world evidence at AMCP Nexus 2025, highlighting that high adherence to SUBLOCADE (monthly injectable buprenorphine) significantly reduces relapse rates and healthcare resource utilization for patients with opioid use disorder (OUD) across both Medicaid and commercially insured populations.
Specifically, Medicaid patients with high adherence experienced lower rates of emergency department visits (48.3% vs. 65.9%), hospital admissions (7.7% vs. 18.2%), and detox visits (9.3% vs. 28.4%) compared to low adherence.
For commercially insured patients, high adherence to SUBLOCADE was associated with fewer emergency room visits (24.2% vs. 38.9%), fewer detox visits (9.6% vs. 20.4%), and nearly half the total medical costs ($23,051 vs. $43,357) compared to low adherence.
The studies also indicated that SUBLOCADE treatment led to larger reductions in acute skin infections (37% lower) and bacteremia (62% lower), suggesting improved management of infectious conditions.

Nov 3, 2025, 1:00 PM

Press Release

Indivior Reports Strong Q3 2025 Results and Raises Full-Year Guidance

INDV

Earnings

Guidance Update

Revenue Acceleration/Inflection

Indivior reported Q3 2025 Total Net Revenue of $314 million, a 2% increase year-over-year, driven by SUBLOCADE Net Revenue of $219 million, which grew 15% year-over-year.
The company's Adjusted EBITDA for Q3 2025 was $120 million, marking a 14% increase from Q3 2024, and Non-GAAP Net Income grew 42% to $93 million.
Indivior has raised its Full-Year 2025 financial guidance, with Total Net Revenue now projected between $1,180 million and $1,220 million and Adjusted EBITDA between $400 million and $420 million.
The company is making progress on its "Indivior Action Agenda," including organizational simplification efforts that are expected to generate at least $150 million in annual expense savings in 2026.

Oct 30, 2025, 12:00 PM

Presentation

Indivior plc Reports Strong Q3 2025 Results and Raises Full-Year Guidance

INDV

Earnings

Guidance Update

Revenue Acceleration/Inflection

Indivior plc reported Q3 2025 total net revenue of $314 million, a 2% increase year-over-year, with SUBLOCADE net revenue growing 15% to $219 million and adjusted EBITDA increasing 14% to $120 million.
The company raised its full-year 2025 financial guidance, now expecting total net revenue between $1.18 billion and $1.22 billion and adjusted EBITDA between $400 million and $420 million, reflecting a 15% increase versus 2024 at the midpoint.
Strategic actions under the "Indivior Action Agenda" are expected to result in an annual reduction of operating expenses of at least $150 million compared to 2025, with the 2026 operating budget not exceeding $450 million.
These actions include consolidating operating footprint, restructuring R&D and medical affairs, discontinuing OPVEE sales and marketing, and optimizing the rest of world business.

Oct 30, 2025, 12:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for INDIVIOR.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are INDIVIOR's strategic priorities?How is INDIVIOR positioned vs competitors?How did INDIVIOR do last quarter?

Let Fintool AI Agent track INDIVIOR's earnings for you

Get instant analysis when filings drop